News
03-20-2013, 12:57 PM
Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor, or TKI, that is being investigated for use in patients with advanced renal cell carcinoma (RCC), or kidney cancer.
More... (http://www.news-medical.net/news/20130319/Tivozanib-an-interview-with-Stephen-L-Eck-MD-PhD-Vice-President-Global-Oncology-Astellas-Pharma-US-Inc-Global-Development.aspx)
More... (http://www.news-medical.net/news/20130319/Tivozanib-an-interview-with-Stephen-L-Eck-MD-PhD-Vice-President-Global-Oncology-Astellas-Pharma-US-Inc-Global-Development.aspx)